Loading clinical trials...
Loading clinical trials...
Phase 1/1b First-in-human Study of Autologous Chimeric Engulfment Receptor T-Cell CER-1236 in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Myelofibrosis (CertainT-1)
Conditions
Interventions
CER-1236
Cyclophosphamide
+2 more
Locations
4
United States
University of California, Davis Comprehensive Cancer Center
Sacramento, California, United States
Colorado Blood Cancer Institute
Denver, Colorado, United States
Sarah Cannon Research Insitute
Nashville, Tennessee, United States
The University of Texas MD Anderson Cancer Center
Houston, Texas, United States
Start Date
April 7, 2025
Primary Completion Date
December 31, 2026
Completion Date
December 31, 2029
Last Updated
March 27, 2026
NCT05564390
NCT06973668
NCT07320235
NCT06782542
NCT07295951
NCT06284486
Lead Sponsor
CERo Therapeutics Holdings, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions